Legacy Technology Holdings, Inc. (LTHO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Legacy Technology Holdings, Inc. (LTHO) trades at $0.00 with AI Score 44/100 (Grade C). Legacy Technology Holdings, Inc. is a healthcare company specializing in genomic preventative medicine and medical software. Market cap: $1,720, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for LTHO: LTHO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LTHO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LTHO: the 1 perspectives are evenly split.
How is this calculated? →Legacy Technology Holdings, Inc. (LTHO) Healthcare & Pipeline Overview
Legacy Technology Holdings, Inc. develops and commercializes a web-based genomic preventative medicine and medical software solution. The company leverages algorithms to analyze patient lifestyle and genetic data, offering personalized health insights within the specialty and generic drug manufacturing sector. It faces competition in a rapidly evolving healthcare technology landscape.
What Is the Investment Thesis for LTHO?
Legacy Technology Holdings, Inc. operates in the high-growth personalized medicine market, leveraging genomic data and lifestyle factors to provide preventative healthcare solutions. However, with a market capitalization of 2K and a negative P/E ratio of -0.18, the company's financial stability is uncertain. Key value drivers include the expansion of its software platform and the acquisition of new customers. Growth catalysts include increasing adoption of personalized medicine and strategic partnerships with healthcare providers. Potential risks include intense competition, regulatory hurdles, and the need for continuous innovation to maintain a competitive edge. Investors should closely monitor the company's ability to achieve profitability and secure funding for future growth.
Based on FMP financials and quantitative analysis
LTHO Key Highlights
- Market Cap of 2K indicates a micro-cap company with high growth potential but also higher risk.
- P/E Ratio of -0.18 suggests the company is currently unprofitable, requiring further investigation into its financial performance.
- Beta of -5.84 indicates a high degree of volatility and a negative correlation with the market, potentially making it a risky investment.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than distributing profits to shareholders.
- Focus on genomic preventative medicine aligns with the growing trend of personalized healthcare, presenting a significant market opportunity.
Who Are LTHO's Competitors?
LTHO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LTHO's Key Strengths?
- Proprietary algorithms for genomic and lifestyle data analysis.
- Focus on personalized preventative medicine.
- Web-based software platform for accessibility.
- Potential for strategic partnerships with healthcare providers.
What Are LTHO's Weaknesses?
- Limited market capitalization of 2K.
- Negative P/E ratio indicating unprofitability.
- High beta suggesting significant volatility.
- Dependence on continuous innovation to maintain competitive edge.
What Could Drive LTHO Stock Higher?
- Increasing adoption of personalized medicine and preventative healthcare solutions.
- Strategic partnerships with healthcare providers and research institutions.
- Potential regulatory approvals for its software platform and genomic analysis tools.
- Expansion into new geographic markets with high demand for personalized healthcare.
- Development of new applications for specific disease areas and patient populations.
What Are the Key Risks for LTHO?
- Intense competition from established pharmaceutical companies and emerging healthcare technology providers.
- Regulatory hurdles and compliance requirements for genomic testing and medical software.
- Data privacy and security breaches compromising patient information.
- Limited financial resources and potential need for additional funding.
- Dependence on key personnel and potential loss of expertise.
What Are the Growth Opportunities for LTHO?
- Expansion of Software Platform: Legacy Technology Holdings has the opportunity to expand its software platform by incorporating additional data sources and analytical capabilities. This could involve integrating wearable device data, expanding the range of genetic markers analyzed, and developing more sophisticated algorithms for risk prediction. The market for personalized health monitoring is projected to reach $70 billion by 2028, providing a significant growth opportunity for the company. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physician groups can provide Legacy Technology Holdings with access to a broader patient base and valuable clinical data. These partnerships can also facilitate the integration of the company's software platform into existing healthcare workflows. The market for healthcare IT solutions is expected to reach $390 billion by 2027, highlighting the potential for strategic alliances. Timeline: Ongoing.
- Direct-to-Consumer Marketing: Legacy Technology Holdings can explore direct-to-consumer marketing strategies to reach individuals who are proactive about their health and interested in personalized preventative care. This could involve offering at-home genetic testing kits, online health assessments, and personalized wellness recommendations. The direct-to-consumer genetic testing market is projected to reach $6.2 billion by 2027, presenting a viable growth avenue. Timeline: 1-2 years.
- Geographic Expansion: Expanding into new geographic markets can significantly increase Legacy Technology Holdings' customer base and revenue potential. This could involve targeting countries with advanced healthcare systems and a growing interest in personalized medicine. The global market for personalized medicine is expected to reach $3.5 trillion by 2030, indicating substantial growth opportunities in international markets. Timeline: 2-3 years.
- Development of New Applications: Legacy Technology Holdings can leverage its core technology to develop new applications for specific disease areas or patient populations. This could involve creating specialized software modules for managing chronic conditions, preventing cardiovascular disease, or optimizing cancer treatment. The market for disease-specific healthcare applications is rapidly expanding, offering opportunities for targeted product development. Timeline: 1-2 years.
What Opportunities Does LTHO Have?
- Expansion of software platform with additional data sources.
- Direct-to-consumer marketing strategies.
- Geographic expansion into new markets.
- Development of new applications for specific disease areas.
What Threats Does LTHO Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and compliance requirements.
- Data privacy and security concerns.
- Rapid technological advancements in the healthcare industry.
What Are LTHO's Competitive Advantages?
- Proprietary algorithms for analyzing genomic and lifestyle data.
- Web-based software platform for easy accessibility.
- Focus on personalized preventative medicine.
- Potential for network effects as more data is collected and analyzed.
What Does LTHO Do?
Legacy Technology Holdings, Inc., incorporated in 2012 and based in Arvada, Colorado, operates within the healthcare sector, focusing on the development and commercialization of a web-based genomic preventative medicine and medical software solution. The company's core offering is a platform that utilizes proprietary algorithms to analyze a comprehensive range of individual patient lifestyle factors. This includes data derived from blood tests, biometrics, dietary habits, environmental exposures, nutraceutical and pharmaceutical usage, and genetic markers. By integrating these diverse data streams, Legacy Technology Holdings aims to provide personalized health insights and recommendations to individuals and healthcare providers. The company's software solution is designed to assist in the early detection and prevention of diseases by identifying potential health risks based on an individual's unique genomic and lifestyle profile. Legacy Technology Holdings targets the growing market for personalized medicine, where healthcare decisions are increasingly tailored to individual patient characteristics. The company's business model centers around the licensing and subscription of its software platform to healthcare providers and potentially directly to consumers. The company aims to establish itself as a key player in the evolving landscape of preventative and personalized healthcare solutions.
What Products and Services Does LTHO Offer?
- Develops web-based genomic preventative medicine software.
- Commercializes medical software solutions.
- Uses algorithms to analyze patient lifestyle data.
- Analyzes blood tests and biometric data.
- Incorporates diet and environmental factors into health assessments.
- Integrates nutraceutical and pharmaceutical data.
- Analyzes genetic markers to identify health risks.
How Does LTHO Make Money?
- Licenses its software platform to healthcare providers.
- Offers subscription-based access to its genomic analysis tools.
- Potentially generates revenue through direct-to-consumer genetic testing services.
What Industry Does LTHO Operate In?
Legacy Technology Holdings, Inc. operates within the rapidly evolving drug manufacturers - specialty & generic industry, which is experiencing a shift towards personalized medicine and preventative healthcare solutions. The market is characterized by increasing demand for tailored treatments based on individual patient characteristics. The competitive landscape includes established pharmaceutical companies, biotechnology firms, and emerging healthcare technology providers. Legacy Technology Holdings aims to differentiate itself through its web-based genomic preventative medicine platform. The company faces competition from firms such as Aravive, Inc. (AREVF), Conatus Pharmaceuticals Inc. (CNNXF), Conformis, Inc. (CSTF), Global Health Partner AB (GBHPF), and Grove, Inc. (GRVE).
Who Are LTHO's Key Customers?
- Healthcare providers seeking personalized medicine solutions.
- Hospitals and clinics looking to improve preventative care.
- Individuals interested in proactive health management.
- Wellness centers and health coaches.
LTHO Valuation & Market Position
With a 2K market cap, Legacy Technology Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, LTHO's quantitative score of 44/100 is below the peer average of 66/100.
ROE 46%Key Financial Metrics
Return on equity for Legacy Technology Holdings, Inc. stands at 45.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
LTHO Financials
Bull Case vs Bear Case
Bull Case
- Proprietary algorithms for genomic and lifestyle data analysis.
- Focus on personalized preventative medicine.
- Web-based software platform for accessibility.
- Potential for strategic partnerships with healthcare providers.
Bear Case
- Limited market capitalization of 2K.
- Negative P/E ratio indicating unprofitability.
- High beta suggesting significant volatility.
- Dependence on continuous innovation to maintain competitive edge.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LTHO Latest News
No recent news available for LTHO.
LTHO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LTHO.
Price Targets
Wall Street price target analysis for LTHO.
LTHO MoonshotScore
What does this score mean?
The MoonshotScore rates LTHO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
LTHO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Legacy Technology Holdings, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information availability and increased volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for higher price volatility due to lower trading volume.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable information about the company.
- Lower regulatory oversight compared to major exchanges.
- Verify the company's registration and legal standing.
- Assess the company's financial condition and ability to continue as a going concern.
- Research the background and experience of the company's management team.
- Review any available financial statements and disclosures.
- Understand the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk management practices.
- Consult with a qualified financial advisor before investing.
- Company incorporated in 2012 suggests some operating history.
- Based in Arvada, Colorado, providing a physical location.
- Focus on genomic preventative medicine aligns with current healthcare trends.
- Development of a web-based software platform indicates technological capabilities.
What Investors Ask About Legacy Technology Holdings, Inc. (LTHO) — Healthcare
What does Legacy Technology Holdings, Inc. do?
Legacy Technology Holdings, Inc. develops and commercializes a web-based genomic preventative medicine and medical software solution. The company uses algorithms to analyze data on individual patient lifestyle factors, such as blood tests, biometrics, diet, environmental, nutraceutical, pharmaceutical, and genetic makers. By integrating these diverse data streams, Legacy Technology Holdings aims to provide personalized health insights and recommendations to individuals and healthcare providers, focusing on early disease detection and prevention.
What are the main risks for LTHO?
Legacy Technology Holdings, Inc. faces several risks inherent to the healthcare and technology sectors. These include intense competition from established pharmaceutical companies and emerging healthcare technology providers, regulatory hurdles and compliance requirements for genomic testing and medical software, and potential data privacy and security breaches compromising patient information. Additionally, the company's limited financial resources and dependence on key personnel pose ongoing risks to its operations and future growth.
What are the key factors to evaluate for LTHO?
Legacy Technology Holdings, Inc. (LTHO) holds an AI score of 44/100 (low). Not financial advice.
How frequently does LTHO data refresh on this page?
LTHO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LTHO's recent stock price performance?
Legacy Technology Holdings, Inc. (LTHO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary algorithms for genomic and lifestyle data analysis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LTHO overvalued or undervalued right now?
Valuing Legacy Technology Holdings, Inc. (LTHO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LTHO?
Before investing in Legacy Technology Holdings, Inc. (LTHO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LTHO to a portfolio?
Key strength of Legacy Technology Holdings, Inc. (LTHO): Proprietary algorithms for genomic and lifestyle data analysis. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Legacy Technology Holdings, Inc.
- AI analysis pending for a more comprehensive assessment.